SANOFICONR · Health Care · 2026-08-21

Sanofi Consumer Healthcare India Ltd

Stage 3 · wk 5In scan: Prop Scan · Breakout WatchMARKET: BULL RISING · 2026-08-21
₹4,222.1
+0.21% today
₹9,738 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited is a subsidiary of Opella Healthcare Participations B.V.

Visit company website →
P/E (TTM)
40.4
Forward 33.8
Earnings Growth (YoY)
+35.7%
Revenue +32.8%
Dividend Yield
1.16%
P/B 27.2
vs 52W High
-20.2%
₹3,999.5 lo₹5,292.5 hi
20.2% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 5
1w13w26w
Week 5 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-6.6%
200 DMA: ₹4,521.2 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.28x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -2.2% vs MA50 -1.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2024-09-13 → 2026-08-21
S? 42w
S2 12w
S4 23w
S1 8w
2024-09-132026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S2 12w → S3 5w → S4 23w → S1 8w → S2 6w → S3 5w current
Total tracked: 100 weeks across 7 stage runs.
1M
-9.2%
3M
-10.8%
6M
+0.1%
YTD
-5.6%
1Y
-18.6%
Scan Membership
Prop Scan
Latest: 2026-06-17
Breakout Watch
Latest: 2026-06-09
7 appearances in last 60 days. First seen: 2025-07-07.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S3
Wk 5 · Vol —x
2026-08-20S3
Wk 5 · Vol —x
2026-08-19S3
Wk 5 · Vol —x
2026-08-18S3
Wk 5 · Vol —x
2026-08-17S3
Wk 5 · Vol —x
2026-08-14S3
Wk 4 · Vol —x
2026-08-13S3
Wk 4 · Vol —x
2026-08-12S3
Wk 4 · Vol —x
2026-08-11S3
Wk 4 · Vol —x
2026-08-10S3
Wk 4 · Vol —x
2026-08-07S3
Wk 3 · Vol —x
2026-08-06S3
Wk 3 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹4,578.2
200 DMA
₹4,521.2
52W High
₹5,292.5
52W Low
₹3,999.5
5D Low
₹4,213.1
Resistance levels (recent highs)
20d High
₹4,745.3
60d High
₹4,948.6
120d High
₹5,026.8
250d High
₹5,292.5
Next resistance
+12.4%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.